RxSight

RXST

Market cap $337M

ALISO VIEJO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced it will be featured in multiple Live Learning Sessions at Booth #2931 during the American Academy of Ophthalmology Annual Meeting (AAO 2025), taking place October 18–20 at the Orange County Convention Center in Orlando, Fla.

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in  RxSight between November 7, 2024 and July 8, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.

NEW YORK , Sept. 23, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. ("RxSight" or the "Company")(NASDAQ: RXST).

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.

NEW YORK--(BUSINESS WIRE)---- $RXST #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm h.

Bragar Eagel & Squire, P.C. Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In RxSight (RXST) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in  RxSight between November 7, 2024 and July 8, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner  Brandon Walker or Marion Passmore directly at (212) 355-4648.

RxSight may be outlining a 'ski-jump' technical pattern, suggesting the potential for a sharp short-term rebound. RXST holds $227 million in cash against $31 million in total liabilities, limiting downside risk with $379 million in equity market cap. The company's cash runway is estimated at 5-10 years, with manageable annual cash burn of $20-30 million.

LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of the securities laws.

LOS ANGELES , Sept. 22, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

NEW YORK, Sept. 21, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against RxSight, Inc. (“RxSight” or “the Company”) (NASDAQ: RXST) and certain of its officers.